This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2q6g

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2q6g.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2q6g.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2q6g| PDB=2q6g | SCENE= }}
{{STRUCTURE_2q6g| PDB=2q6g | SCENE= }}
-
'''Crystal structure of SARS-CoV main protease H41A mutant in complex with an N-terminal substrate'''
+
===Crystal structure of SARS-CoV main protease H41A mutant in complex with an N-terminal substrate===
-
==Overview==
+
<!--
-
Coronaviruses (CoVs) can infect humans and multiple species of animals, causing a wide spectrum of diseases. The coronavirus main protease (M(pro)), which plays a pivotal role in viral gene expression and replication through the proteolytic processing of replicase polyproteins, is an attractive target for anti-CoV drug design. In this study, the crystal structures of infectious bronchitis virus (IBV) M(pro) and a severe acute respiratory syndrome CoV (SARS-CoV) M(pro) mutant (H41A), in complex with an N-terminal autocleavage substrate, were individually determined to elucidate the structural flexibility and substrate binding of M(pro). A monomeric form of IBV M(pro) was identified for the first time in CoV M(pro) structures. A comparison of these two structures to other available M(pro) structures provides new insights for the design of substrate-based inhibitors targeting CoV M(pro)s. Furthermore, a Michael acceptor inhibitor (named N3) was cocrystallized with IBV M(pro) and was found to demonstrate in vitro inactivation of IBV M(pro) and potent antiviral activity against IBV in chicken embryos. This provides a feasible animal model for designing wide-spectrum inhibitors against CoV-associated diseases. The structure-based optimization of N3 has yielded two more efficacious lead compounds, N27 and H16, with potent inhibition against SARS-CoV M(pro).
+
The line below this paragraph, {{ABSTRACT_PUBMED_18094151}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 18094151 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_18094151}}
==About this Structure==
==About this Structure==
Line 32: Line 36:
[[Category: Main protease]]
[[Category: Main protease]]
[[Category: Sars-cov]]
[[Category: Sars-cov]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 14:26:15 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 02:45:45 2008''

Revision as of 23:45, 27 July 2008

Image:2q6g.png

Template:STRUCTURE 2q6g

Crystal structure of SARS-CoV main protease H41A mutant in complex with an N-terminal substrate

Template:ABSTRACT PUBMED 18094151

About this Structure

2Q6G is a Single protein structure of sequence from Sars coronavirus. Full crystallographic information is available from OCA.

Reference

Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design., Xue X, Yu H, Yang H, Xue F, Wu Z, Shen W, Li J, Zhou Z, Ding Y, Zhao Q, Zhang XC, Liao M, Bartlam M, Rao Z, J Virol. 2008 Mar;82(5):2515-27. Epub 2007 Dec 19. PMID:18094151

Page seeded by OCA on Mon Jul 28 02:45:45 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2q6g"
Personal tools